At a glance
ClinicalIndex Comparison RecordN/ACompleted· 579 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis
In Brief
An observational study for Chronic Liver Disease. Completed, enrolled 579 participants across 4 sites in 2 countries.
Detailed Summary
The objectives of this study are: * To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events * To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biopsy. * To evaluate the ability of the MBT to predict each of the individual liver related complications.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Liver Disease
CountriesIsrael, United States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionOct 2018
Study CompletionNov 2018
TodayJul 2026
First PostedMar 11, 2014
Enrollment StartMar 1, 2014
Primary CompletionOct 1, 2018
Study CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 12.3 years ago